TipRanks
Go Ultimate55% OFF

Medical Ikkou Group Co., Ltd. (3353) AI Stock Analysis

JP:3353

Medical Ikkou Group Co., Ltd.

(TSE/TYO:3353)

Select Model
Rating:84Outperform
Price Target:JPY 3,343.00â–²(21.39% Upside)
Action:reiterated
Date:08/04/26

The strong overall score of 84 is primarily driven by an exceptionally attractive valuation, offering a low P/E ratio and a high dividend yield. This is supported by consistent revenue growth, a strengthening balance sheet, and bullish technical indicators. The score is only tempered by weak free cash flow generation, which warrants investor monitoring.

Positive Factors
Improving Revenue GrowthThe company has maintained positive top-line momentum, with revenue growth improving materially across recent periods. Sustained expansion can support pharmacy scale, strengthen operating leverage over time, and provide a foundation for continued earnings growth.
Negative Factors
Weak Cash ConversionVery weak conversion of accounting earnings into cash raises concerns about working-capital swings or ongoing investment requirements. If persistent, this could constrain reinvestment, dividends, and debt reduction despite reported profitability.

Medical Ikkou Group Co., Ltd. (3353) vs. iShares MSCI Japan ETF (EWJ)

-5%0%5%10%15%20%25%30%JP:3353+8.24%EWJ+16.91%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 10.39B
Dividend Yield
4.36%
Average Volume (3M)
1,786
Price to Earnings (P/E)
7.1
Beta (1Y)
0.25
Revenue Growth
6.91%
EPS Growth
33.61%
Country
Japan
Employees
1,608
Sector
Industrials
Sector Strength
63
Industry
Conglomerates

Medical Ikkou Group Co., Ltd. Business Overview & Revenue Model

Company Description

Medical Ikkou Group Co.,Ltd. is a Japanese enterprise primarily known for managing dispensing pharmacies across the nation. Beyond its extensive pharmacy operations, the company diversified its activities to include the management of various care fac...

How the Company Makes Money

Medical Ikkou Group generates revenue mainly through (1) dispensing pharmacy operations, where it fills outpatient prescriptions issued by clinics and hospitals and receives payments comprised of reimbursed dispensing fees and medicine costs under Ja...

Medical Ikkou Group Co., Ltd. Financial Statement Overview

Summary

Solid financial foundation marked by consistent top-line growth and a de-leveraged balance sheet, though partially offset by weak free cash flow conversion and low operating cash flow to debt coverage.

Income Statement

82Very Positive

Balance Sheet

85Very Positive

Cash Flow

60Neutral
Financial statement breakdown
BreakdownTTMFeb 2026Feb 2025Feb 2024Feb 2023Feb 2022
Income Statement
Total Revenue54.98B54.98B48.39B39.90B33.90B33.60B
Gross Profit6.36B6.36B5.61B4.38B2.97B3.37B
EBITDA2.63B2.63B2.46B2.34B1.78B2.15B
Net Income1.28B1.28B1.13B1.04B759.60M852.33M
Balance Sheet
Total Assets37.52B37.52B34.23B31.66B27.51B29.09B
Cash, Cash Equivalents and Short-Term Investments6.12B6.12B6.77B7.70B6.44B7.99B
Total Debt10.36B10.36B10.04B9.60B9.15B11.35B
Total Liabilities21.24B21.24B19.52B17.82B14.90B17.17B
Stockholders Equity15.63B15.63B14.10B13.24B12.05B11.38B
Cash Flow
Free Cash Flow0219.98M201.34M3.97B995.40M812.29M
Operating Cash Flow01.21B1.20B4.28B1.31B1.14B
Investing Cash Flow0-1.81B-1.13B-3.22B-477.52M539.48M
Financing Cash Flow0-283.62M-1.03B277.76M-2.37B-690.26M

Medical Ikkou Group Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

JP:3353 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:3353JP:335384OutperformJPY 9.54B7.11―4.36%6.91%33.61%
JP:7509JP:750979OutperformJPY 6.90B4.73―3.37%5.55%21.45%
JP:7119JP:711969NeutralJPY 20.71B17.63―2.13%-1.50%83.80%
JP:9248JP:924867NeutralJPY 14.03B5.22―3.84%8.74%―
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
JP:2462JP:246256NeutralJPY 27.96B12.65―4.15%5.94%-0.10%
JP:6838JP:683854NeutralJPY 10.39B20.07―0.91%――

* Industrials Sector Average

Performance Comparison

0%50%100%150%200%JP:3353JP:2462JP:6838JP:7119JP:7509JP:9248Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:3353 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:3353Medical Ikkou Group Co., Ltd.2754.00250.119.99%
JP:2462LIKE, Inc.1446.007.780.54%
JP:6838Tamagawa Holdings Co., Ltd.1095.00309.5339.41%
JP:7119halmek holdings Co.,Ltd.1828.00516.5539.39%
JP:7509I. A Group Corporation4595.00570.9614.19%
JP:9248People, Dreams & Technologies Group Co., Ltd.1562.0014.360.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 04, 2026